Very late antigen 1 blockade markedly promotes survival of corneal allografts.
Arch Ophthalmol
; 125(6): 783-8, 2007 Jun.
Article
em En
| MEDLINE
| ID: mdl-17562989
ABSTRACT
OBJECTIVE:
To investigate the role of very late antigen 1 (VLA-1) (also known as integrin receptor alpha(1)beta(1)) in corneal transplantation inflammation and allograft survival.METHODS:
Cell infiltration and vasculogenesis (both angiogenesis and lymphangiogenesis) associated with allodisparate corneal transplantation were assessed in VLA-1-deficient conditions and controls by immunofluorescent microscopic studies. Corneal allograft survival was also assessed after anti-VLA-1 antibody treatment and in VLA-1 knockout recipient mice.RESULTS:
Anti-VLA-1 antibody treatment leads to a profound reduction in the granulocytic, monocytic, and T-cell infiltration after corneal transplantation. In addition, corneal angiogenesis and lymphangiogenesis were both significantly suppressed in VLA-1 knockout mice. Remarkably, universal graft survival was observed in both anti-VLA-1 antibody treatment and knockout mice.CONCLUSIONS:
Very late antigen 1 blockade markedly reduces inflammation and inflammation-induced tissue responses, including vasculogenic responses, associated with corneal transplantation and promotes allograft survival. CLINICAL RELEVANCE These studies offer insights into important integrin-mediated mechanisms of corneal transplant-related inflammation and provide possible new integrin-based immunotherapies for transplant rejection.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Transplante de Córnea
/
Córnea
/
Integrina alfa1beta1
/
Sobrevivência de Enxerto
Limite:
Animals
Idioma:
En
Ano de publicação:
2007
Tipo de documento:
Article